Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

Thrombocytopenia is a common issue in patients with advanced liver disease due to decreased thrombopoietin production and hypersplenism sequestration from portal hypertension. The degree of thrombocytopenia is often a maker of both severity of liver disease.

There are several TPO agonists on the market. Romiplostin is approved for hematologic disorders. It has been studied in small studies for patients with liver disease, but there were safety concerns for portal vein thrombosis. Eltrombopag was ...